UPDATE: Ladenburg Thalmann Lowers United Therapeutics' PT

According to a research report published earlier today, Ladenburg Thalmann has decreased United Therapeutics'

PT from $61 to $58. In the report, Ladenburg Thalmann said, "UTHR reported revenues of $110.5 million, $70.1 million and $22.3 million for Remodulin, Tyvaso and Adcirca for 1Q12 which was essentially inline with consensus estimates. We continue to be impressed by the strong revenue growth demonstrated by Tyvaso and we expect this product to be sustainable driver of increased revenues." Ladenburg Thalmann maintains its Buy rating on United Therapeutics, which is currently trading at $44.11.